You are here: Home » Economy & Policy » News
Business Standard

Price cap on drugs, medical devices help patients save Rs 11,365 cr: Govt

Consumers also benefited by Rs 4,450 crore from price control of coronary stents

Medical Costs

Press Trust of India  |  New Delhi 

Pharmaceuticals, drugs, pharma industry, medical, health, lab

Capping of prices of medicines and medical devices, including stents and knee implants, has helped patients save a total of Rs 11,365.61 crore till December 2017, Parliament was informed today.

Ceiling prices of 851 formulations (including two coronary stents) under Revised Schedule - I based on National List of Essential Medicines (NLEM), 2015, were fixed till December 2017, Minister of State for Chemicals & Fertilisers Mansukh L Mandaviya said in a written reply to the Rajya Sabha.

The government by implementing the provisions of DPCO, 2013 has helped the consumers save Rs 11,365.61 crore, Mandaviya said.

The National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling prices of medicines listed in the Schedule - I of Drugs (Prices Control) Order (DPCO), 2013.

Savings from capping of price of drugs under NLEM 2011 were Rs 2,422.24 crore, while the same for NLEM 2015 were 2,643.37 crore.

Consumers also benefited by Rs 4,450 crore from price control of coronary stents. Similarly, price cap on knee implants resulted in savings of 1,500 crore and Rs 350 crore savings resulted from cardio and anti-diabetic category till December 2017, the minister added.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, December 29 2017. 18:28 IST